2026 Interim report
Filed with HKEX · Stock code 6833 · · 66 pages · English and Chinese
Summary by 6ix AI
The report indicates a decrease in revenue and net profit compared to the same period last year, primarily due to challenges in the pharmaceutical market. Despite the decline in revenue, the gross profit margin improved, attributed to lower sales costs and currency fluctuations. The company has decided not to declare any interim dividend for this reporting period.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Sinco Pharmaceuticals Holdings Ltd. on 6ix
Earlier from Sinco Pharmaceuticals
- Sinco Pharmaceuticals Holdings: Proposals for general mandates to issue shares and repurchase shares, re-election of directors and notice of annual general meeting
- Change of joint company secretary change of authorised representative and waiver from strict compliance with rules 3.28 and 8.17 of the listing rules
Later from Sinco Pharmaceuticals
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2026
Follow Sinco Pharmaceuticals into a list and get an email when it puts out news.
Follow Sinco Pharmaceuticals